Sign up
Pharma Capital

Cellmid gaining ground in USA and China following advances in Japan and Australia

Cellmid Limited (ASX:CDY) CEO Maria Halasz provides a show and tell updating Proactive Investors on progress and strategies for the company’s international portfolio of products, including the world’s first non-injectable filler product.

Speaking on growth drivers, Halasz says, "as far as our consumer health business is concerned; we definitely have new product ranges, we've got our e-commerce platform and new distribution channels in new geographic regions that will drive sales and growth. As far as our biotech portfolio is concerned... we are meeting our intellectual leaders, but the actual patents are owned by the company... it's cost effective but more importantly it really is wide spread development of a really large portfolio of patents."

 

View full CDY profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.